

Cited in: EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.

Reviews

**Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group**

S.G. Armato III (USA), R.J. Francis (Australia), S.I. Katz (USA), G. Ak (Turkey), I. Opitz (Switzerland), E. Gudmundsson (USA), K.G. Blyth (UK), A. Gupta (Canada) 108

**CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome**

S.-H.I. Ou, V.W. Zhu (USA) 201

Original Research Articles

**Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies**

Y. Yoneshima, K. Tanaka, Y. Shiraishi, K. Hata, H. Watanabe, T. Harada, K. Otsubo, E. Iwama, H. Inoue, S. Masuda, Y. Nakanishi, I. Okamoto (Japan) 5

**Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer**

S. Zhao, G. Gao, W. Li, X. Li, C. Zhao, T. Jiang, Y. Jia, Y. He, A. Li, C. Su, S. Ren, X. Chen, C. Zhou (PR China) 10

**Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study**

Y.-L. Wu, C. Zhou, S. Lu, S. Qin, H. Pan, G. Wu, Y. Cheng, X. Liu, B. Han, Y. Zhu, Z. Zhong, C. Huang, L. Chen, H. Liang, E. Li, G. Jiang (China) 18

**PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of  $\beta$ -catenin and snail/slug in non-small cell lung carcinoma cells**

E. Perumal, K. So Youn, S. Sun, J. Seung-Hyun, M. Suji, L. Jieying, C. Yeun-Jun (Republic of Korea) 25

**High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes**

T. Ahmadzada, K. Lee, C. Clarke, W.A. Cooper, A. Linton, B. McCaughan, R. Asher, S. Clarke (Australia), G. Reid (Australia, New Zealand), S. Kao (Australia) 35

**Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy**

H. Li, C. Wang, Z. Wang, Y. Hu, G. Zhang, M. Zhang, X. Zheng, X. Zhang, J. Yang, Z. Ma, H. Wang (China) 42

**Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11**

L. La Fleur, E. Falk-Sörqvist, P. Smeds, A. Berglund, M. Sundström, J.S. Mattsson, E. Brandén, H. Koyi, J. Isaksson, H. Brunnström, M. Nilsson, P. Micke, L. Moens, J. Botling (Sweden) 50

(Contents continued overleaf)



<b>Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H</b>	
M.A. Gubens, L.V. Sequist, J.P. Stevenson, S.F. Powell, L.C. Villaruz, S.M. Gadgeel, C.J. Langer, A. Patnaik, H. Borghaei, S.I. Jalal, J. Fiore, S. Saraf, H. Raftopoulos, L. Gandhi (USA)	59
<b>Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study</b>	
O. Arrieta, F. Barrón, F. Maldonado, L. Cabrera, J.F. Corona-Cruz, M. Blake, L.A. Ramírez-Tirado, Z.L. Zatarain-Barrón (Mexico), A.F. Cardona (Colombia), O. García (Mexico), O. Arén (Chile), J. De la Garza (Mexico)	67
<b>Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors</b>	
T. Jiang, Y. Bai, F. Zhou, W. Li, G. Gao, C. Su, S. Ren, X. Chen, C. Zhou (PR China)	76
<b>Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer</b>	
K. Lee, Y. Kim, H.A. Jung, S.-H. Lee, J.S. Ahn, M.-J. Ahn, K. Park, Y.-L. Choi, J.-M. Sun (Republic of Korea)	87
<b>Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes</b>	
W. Haque, V. Verma, E.B. Butler, B.S. Teh (USA)	93
<b>The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer</b>	
O.P. Geerse, D. Brandenbarg, H.A.M. Kerstjens, A.J. Berendsen, S.F.A. Duijts, H. Burger, G.A. Holtman (the Netherlands), J.E.H.M. Hoekstra-Weebers (the Netherlands, The Netherlands), T.J.N. Hiltermann (the Netherlands)	101
<b>Correlation study between dual source CT perfusion imaging and the microvascular composition of solitary pulmonary nodules</b>	
M. Wang, B. Li, H. Sun, T. Huang, X. Zhang, K. Jin, F. Wang, X. Luo (China)	115
<b>Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening</b>	
L.R. Meltzer, M. Unrod, V.N. Simmons, K.O. Brandon, B. Piñeiro, A.M. Palmer, T.H. Brandon (USA)	121
<b>Nivolumab-refractory patients with advanced non-small-cell lung cancer</b>	
A. Costantini, V. Fallet, J. Corny, S. Friard, C. Chouaid, B. Duchemann, E. Giroux-Leprieur, L. Taillade, L. Doucet, S. Brosseau, M. Wislez, J. Tredaniel, J. Cadranet (France)	128
<b>A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy</b>	
H. Wang, L. Sun, Y. Sang, X. Yang, G. Tian, Z. Wang, J. Fang, W. Sun, L. Zhou, L. Jia (People's Republic of China), M.-S. Tsao (Canada)H. Shi, D. Lin (People's Republic of China)	135
<b>Patient reported outcome data as performance indicators in surgically treated lung cancer patients</b>	
M.M. Brønserud, M. Iachina, A. Green, M. Groenvold, E. Jakobsen (Denmark)	143
<b>Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study</b>	
S. Schmid, D. Klingbiel, S. Aeppli, C. Britschgi, O. Gautschi, M. Pless, S. Rothschild, L. Wannesson, W. Janthur, D. Foerbs, I. Demmer, W. Jochum, M. Früh (Switzerland)	149
<b>Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis</b>	
C.C. Foster, C.G. Rusthoven, D.J. Sher, L. Feldman, M. Pasquinelli, M.T. Spiotto, M. Koshy (USA)	162
<b>IKKβ targeting reduces KRAS-induced lung cancer angiogenesis <i>in vitro</i> and <i>in vivo</i>: A potential anti-angiogenic therapeutic target</b>	
T.C. Carneiro-Lobo, L.C. Scalabrini, L.d.S. Magalhães, L.B. Cardeal, F.S. Rodrigues, E.O. dos Santos (Brazil), A.S. Baldwin (USA), E. Levantini (USA, Italy), R.J. Giordano, D.S. Bassères (Brazil)	169
<b>Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)</b>	
B.C.M. Hermans, J.L. Derks, E. Thunnissen, R.J. van Suylen, M.A. den Bakker, H.J.M. Groen, E.F. Smit, R.A. Damhuis, E.C. van den Broek, C.M. Stallinga, G.M. Roemen, E.J.M. Speel, A.-M. Dingemans (the Netherlands)	179
<b>Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia</b>	
M. Yoshimura, Y. Kinoshita, M. Hamasaki, S. Matsumoto, T. Hida, Y. Oda, A. Iwasaki, K. Nabeshima (Japan)	187

<b>Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung</b> T. Muley, Y. He, V. Rolny, B. Wehnl (Germany), A. Escherich (Switzerland), A. Warth, C. Stolp, M.A. Schneider, M. Meister, F.J. Herth (Germany), F. Dayyani (Switzerland)	194
<b>Lung cancer mortality in Australia in the twenty-first century: How many lives can be saved with effective tobacco control?</b> Q. Luo, J. Steinberg, D.L. O'Connell, X.Q. Yu, M. Caruana, S. Wade (Australia), F. Pesola (UK), P.B. Grogan, A. Dessaix, B. Freeman, S. Dunlop (Australia), P. Sasieni (UK), T. Blakely, E. Banks, K. Canfell (Australia)	208
<b>Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study</b> C.-C. Steffens, C. Elender, U. Hutzschenreuter, S. Dille, A. Binnering, L. Spring, M. Jänicke, N. Marschner (Germany)	216
<i>Short Communications</i>	
<b>Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer</b> K. Zhou, J. Zhou, J. Huang, N. Zhang, L. Bai, Y. Yang, Q. Li (China)	1
<b>The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment</b> Y. Sakata, K. Kawamura, K. Ichikado, N. Shingu, Y. Yasuda, Y. Eguchi, K. Anan, J. Hisanaga, T. Nitawaki, M. Iio, Y. Sekido, A. Nakano, T. Sakagami (Japan)	159
<i>Case Reports</i>	
<b>MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma</b> Y.L. Miao, Q.Q. Xu (China)	84
<b>Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis</b> N. de Rouw, S. Croes, R. Posthuma, D.E. Agterhuis, J.J.A.O.. Schoenmaekers, H.J Derijks, D.M. Burger, A.M. Dingemans, R. ter Heine (the Netherlands)	156
<i>Corrigenda</i>	
<b>Corrigendum to “Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer” [Lung Cancer 128 (2019) 152-157]</b> A. Ono, M. Isaka, M. Serizawa, K. Omae, H. Kojima, K. Nakashima, S. Omori, K. Wakuda, H. Kenmotsu, T. Naito, H. Murakami, K. Urakami, T. Nagashima, T. Sugino, M. Kusuhara, T. Takahashi, K. Yamaguchi, Y. Ohde (Japan)	226